Position in EPRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$66,100
New position
Shares Held
10,000
first reported quarter
Ownership
0.015%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#58
of 68 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Lynx1 Capital Management LP holds $865,408,538 across 26 Biotechnology names. EPRX ranks #25 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GHRS |
GH Research PLC
|
13,263,288 | $356,517,181 | |
| 2 | CGEM |
Cullinan Therapeutics, Inc.
|
8,963,500 | $163,225,335 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
4,038,404 | $132,136,578 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
3,408,937 | $126,505,652 | |
| 5 | CCCC |
C4 Therapeutics, Inc.
|
7,326,691 | $34,215,646 | |
| 6 | KRRO |
Korro Bio, Inc.
|
1,538,296 | $20,274,741 | |
| 7 | TCRX |
TScan Therapeutics, Inc.
|
8,019,148 | $7,858,765 | |
| 8 | DTIL |
Precision Biosciences Inc
|
950,466 | $7,470,662 |
All Filings in EPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $66,100 | 10,000 | Shares | Other | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||